Latest News
ObesityWeek 2026 Preview: The Data to Watch in Washington
ObesityWeek 2026 runs from 14 to 17 November in National Harbor, Maryland, just outside Washington. The meeting is The Obesity Society’s 44th annual gathering. Novo Nordisk arrives with 26 abstracts, including the first results from REDEFINE 9, its lower-dose...
Latest News
Redrawing the Limits of “Undruggable” Proteins
For most of modern target-based drug discovery's history, many biologically important targets have been sidelined as undruggable proteins: structural scaffolds and transcription factors with no active site to inhibit, proteins presenting flat surfaces with no pocket...
Roche Hansoh ADC Deal: What Does Roche Get for $400 Million?
The Roche Hansoh ADC deal gives Roche rights outside Greater China to a portfolio of early antibody-drug conjugates. In return, Roche pays $400 million upfront and $110 million on the first anniversary. Hansoh Pharmaceutical announced the strategic collaboration and...
When Will Merck KGaA’s Silence Therapeutics Acquisition Close?
Merck KGaA, Darmstadt, Germany, expects the Silence Therapeutics acquisition to close in the first quarter of 2027. It will pay $20.00 in cash per American depositary share (ADS). That values Silence at about $1.3 billion. The companies announced the deal on 19...
Function Is the Endpoint: Why Aging Research Should Track Reserve
Ask older adults what they fear about aging and few of them name a number. They name the stairs. They name the low chair they cannot get out of, the groceries they cannot carry in from the car, the day they need someone's help to stay at home. That is the question...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Neurodegeneration Pipeline 2026: Genetic Medicine Leads
Last updated 5 November 2026. The FDA accepted uniQure’s Huntington’s gene therapy application for priority review, with a target action date of 1 May 2027. The neurodegeneration pipeline looks very different from the one that opened 2026. Two events in the first week...
The Future of Collagen Hydrogels in Regenerative Medicine
Collagen hydrogels are still the benchmark for regenerative medicine because they provide cells with an environment that feels biologically familiar. However, the next challenge within this field is no longer proving whether or not collagen works, but in capably...
Novo Nordisk Halts Two IL-6 Heart Failure Trials for Futility
Novo Nordisk has stopped two Phase 3 IL-6 heart failure trials on the advice of an independent monitoring committee. The company notified trial investigators on Friday 4 September 2026. Trade press reported the decision on Monday 7 September. Both studies, HERMES and...
After EMBRAZE: The Wider Race to Preserve Muscle During GLP-1 Treatment
When results from the phase 2 EMBRAZE trial were published in Nature Medicine in June, apitegromab’s combination with tirzepatide became the most visible evidence yet that pharmacological muscle preservation during GLP-1 treatment might be achievable.¹ But...
Is RNA Potency the Problem? Creative Biolabs Webinar on saRNA Delivery
The next breakthrough in RNA therapeutics may depend less on making RNA more powerful and more on solving how efficiently it reaches and functions inside target cells. Creative Biolabs will host the upcoming webinar "Engineering saRNA Delivery Systems for...
Weekly News Roundup | 07 September 2026
Life science news 7 September 2026: two US approvals, a UK suspension, a Phase 3 failure and four global deals. PharmaEssentia won FDA approval for Besremi in essential thrombocythemia, a label expansion for the interferon therapy. The MHRA suspended Avacopan Vifor...
Alexander Disease Treatment Approved: What It Means for UK Access
The United States Food and Drug Administration has approved the first Alexander disease treatment. Zanvastro (zilganersen) was cleared on 3 September 2026 for paediatric and adult patients. Ionis Pharmaceuticals developed the antisense oligonucleotide. The decision...
Pelacarsen Trial Miss Leaves Lp(a) Lowering Unproven
Novartis has reported that the pelacarsen trial missed its primary endpoint. The Phase III study, called Lp(a)HORIZON, enrolled 8,323 patients with established cardiovascular disease and elevated lipoprotein(a). The company announced the topline result on 4 September...
Ivonescimab Overall Survival Win Leaves the Key Numbers Undisclosed
Akeso has reported that ivonescimab beat pembrolizumab on overall survival in a Chinese Phase III trial. HARMONi-2 is the fourth Phase III trial of ivonescimab to meet an overall survival endpoint. The ivonescimab overall survival result is the first against...
New Biology, New Opportunities in Women’s Health
Capital is moving into women’s health. But the science may give it even more reason to stay. Across the field, substantial unmet need is converging with rapidly advancing science and enormous areas of unexplored biology. Advances in genetics, molecular biology,...
Clinical Trials Roundup | 4 Sept 2026
Cytokinetics' aficamten meets both primary endpoints in the Phase 3 ACACIA-HCM trial in non-obstructive hypertrophic cardiomyopathy, Takeda and Protagonist's Mimrylo receives FDA approval as the first hepcidin mimetic for polycythaemia vera, Gilead's Bixlenvo is...
The Scale-Up Test
A lab result is only the beginning I have spent close to 20 years developing pharmaceutical, nutraceutical and consumer health products. One lesson has followed me through almost every role: a formula can work beautifully in the laboratory and still become a problem...
Neurodegeneration Pipeline 2026: Genetic Medicine Leads
Last updated 5 November 2026. The FDA accepted uniQure’s Huntington’s gene therapy application for priority review, with a target action date of 1 May 2027. The neurodegeneration pipeline looks very different from the one that opened 2026. Two events in the first week...
The Future of Collagen Hydrogels in Regenerative Medicine
Collagen hydrogels are still the benchmark for regenerative medicine because they provide cells with an environment that feels biologically familiar. However, the next challenge within this field is no longer proving whether or not collagen works, but in capably...
Novo Nordisk Halts Two IL-6 Heart Failure Trials for Futility
Novo Nordisk has stopped two Phase 3 IL-6 heart failure trials on the advice of an independent monitoring committee. The company notified trial investigators on Friday 4 September 2026. Trade press reported the decision on Monday 7 September. Both studies, HERMES and...
After EMBRAZE: The Wider Race to Preserve Muscle During GLP-1 Treatment
When results from the phase 2 EMBRAZE trial were published in Nature Medicine in June, apitegromab’s combination with tirzepatide became the most visible evidence yet that pharmacological muscle preservation during GLP-1 treatment might be achievable.¹ But...
Is RNA Potency the Problem? Creative Biolabs Webinar on saRNA Delivery
The next breakthrough in RNA therapeutics may depend less on making RNA more powerful and more on solving how efficiently it reaches and functions inside target cells. Creative Biolabs will host the upcoming webinar "Engineering saRNA Delivery Systems for...
Weekly News Roundup | 07 September 2026
Life science news 7 September 2026: two US approvals, a UK suspension, a Phase 3 failure and four global deals. PharmaEssentia won FDA approval for Besremi in essential thrombocythemia, a label expansion for the interferon therapy. The MHRA suspended Avacopan Vifor...
Alexander Disease Treatment Approved: What It Means for UK Access
The United States Food and Drug Administration has approved the first Alexander disease treatment. Zanvastro (zilganersen) was cleared on 3 September 2026 for paediatric and adult patients. Ionis Pharmaceuticals developed the antisense oligonucleotide. The decision...
Pelacarsen Trial Miss Leaves Lp(a) Lowering Unproven
Novartis has reported that the pelacarsen trial missed its primary endpoint. The Phase III study, called Lp(a)HORIZON, enrolled 8,323 patients with established cardiovascular disease and elevated lipoprotein(a). The company announced the topline result on 4 September...
Ivonescimab Overall Survival Win Leaves the Key Numbers Undisclosed
Akeso has reported that ivonescimab beat pembrolizumab on overall survival in a Chinese Phase III trial. HARMONi-2 is the fourth Phase III trial of ivonescimab to meet an overall survival endpoint. The ivonescimab overall survival result is the first against...
New Biology, New Opportunities in Women’s Health
Capital is moving into women’s health. But the science may give it even more reason to stay. Across the field, substantial unmet need is converging with rapidly advancing science and enormous areas of unexplored biology. Advances in genetics, molecular biology,...
Clinical Trials Roundup | 4 Sept 2026
Cytokinetics' aficamten meets both primary endpoints in the Phase 3 ACACIA-HCM trial in non-obstructive hypertrophic cardiomyopathy, Takeda and Protagonist's Mimrylo receives FDA approval as the first hepcidin mimetic for polycythaemia vera, Gilead's Bixlenvo is...
The Scale-Up Test
A lab result is only the beginning I have spent close to 20 years developing pharmaceutical, nutraceutical and consumer health products. One lesson has followed me through almost every role: a formula can work beautifully in the laboratory and still become a problem...
Featured Articles
Further News
ACTO Achieves Veeva Gold Product Partner Status
Validated integrations with Veeva applications help life sciences field teams train, practice, and execute with approved content and real time intelligence Toronto and New York, 2 September 2026 ACTO, uniting human intelligence with empathetic AI in life sciences,...
Huntington Gene Therapy Submission Reaches FDA and MHRA
uniQure filed for regulatory approval of its Huntington’s disease gene therapy on 2 September 2026. The Huntington gene therapy submission went to two agencies. One is the US Food and Drug Administration. The other is the UK Medicines and Healthcare products...
GLP-1 Indications: The 2026 Regulatory Status Map
The list of approved GLP-1 indications now reaches well beyond weight loss and glycaemic control. Regulators in three major markets have licensed the class across cardiology, nephrology and hepatology. Other conditions carry positive phase 3 data but no licence at...
AI in MedTech: Accelerating the Product Development Lifecycle
Developing a new medical device is a lengthy, complex process that typically takes between three to seven years from conception to market [1]. For MedTech companies operating within highly regulated environments where compliance and patient safety are paramount,...
Avacopan UK Suspension Follows Retracted Trial Data
The avacopan UK suspension took effect on 1 September 2026. The Medicines and Healthcare products Regulatory Agency stopped supply of the medicine to new patients that day. It also signalled its intention to revoke the UK marketing authorisation on 1 March 2027. The...
Midlife Metabolic Change: How Behaviour, Nutrition and Stress Shape Health
Midlife marks one of the most significant physiological transitions in the human lifespan. For many individuals, particularly those navigating perimenopause and menopause, metabolic stability becomes harder to maintain, appetite signals shift, energy becomes less...
UK Animal Testing Deadline: What December Actually Requires
The UK animal testing deadline that matters most falls at the end of December. By then, regulatory testing on animals for skin irritation, eye irritation and skin sensitisation is meant to stop. It is the largest of a cluster of targets the Replacing Animals in...
AI in IVF: Ethical and Legal Limits of Algorithmic Decision-Making
AI embryo selection tools can support clinical judgment, but current evidence does not justify treating an algorithmic score as a clinical verdict. A prediction is not a decision Artificial intelligence is entering in vitro fertilisation at one of its most...
Autoimmune CAR-T Safety Under Review as Novartis Halts Eight Trials
Autoimmune CAR-T safety has moved to the centre of the cell therapy agenda. Novartis has halted eight clinical studies of its experimental CD19 CAR-T therapy rapcabtagene autoleucel. The company acted after three fatal cases of a severe inflammatory reaction. Bristol...
What a Hospitalist’s Floor Sees That Health AI Doesn’t
Two rooms that rarely talk I spend my working life in two rooms that almost never talk to each other. The first is the hospital floor, where I care for several thousand patients a year as an attending physician. The second is the conference room, where I evaluate...
Screen Failures Are Data Too: What They Reveal About Trial Design
A single screen failure tells us something about a patient. A pattern of screen failures may tell us something about the trial. Clinical research is very good at studying the patients who make it into a trial. We analyze their baseline characteristics, laboratory...
Licensing versus Acquisition: How Pharma Chooses
On 26 August 2026, SK Biopharmaceuticals agreed to license an epilepsy platform from Biohaven. Sixteen days earlier, Jazz Pharmaceuticals agreed to buy an epilepsy biotech outright. Same disease area, same month, two opposite structures. The licensing versus...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.